BioRexis
United
About BioRexis
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $38.0M
- Funding stage: M&A
- Last round: Series B (Mar 2004)
- Website: biorexis.com
Industries & Categories
Health Care, Insurance, Oncology, Therapeutics
Canonical: https://fsome.com/organization/biorexis-2420733 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.